Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities
- PMID: 8621380
- DOI: 10.1074/jbc.271.10.5309
Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities
Abstract
The c-ret proto-oncogene encodes a receptor tyrosine kinase which plays an important role in neural crest as well as kidney development. Genetic studies have demonstrated that germ line mutations in the ret oncogene are the direct cause of multiple endocrine neoplasia (MEN) 2A and 2B, familial medullary thyroid carcinoma (FMTC), and Hirschsprung's disease. However, despite the large body of genetic and biological evidence suggesting the importance of RET in development and neoplastic processes, the signal transduction mechanisms of RET remain unknown. To begin to understand the molecular mechanisms of the disease states caused by mutations in RET, the patterns of autophosphorylation of the wild-type RET and the MEN mutants were studied using site-directed mutagenesis and phosphopeptide mapping. Among the 6 autophosphorylation sites found in the wild-type RET receptor, the MEN2B mutant lacked phosphorylation at Tyr-1096, leading to decreased Grb2 binding, while simultaneously creating a new phosphorylation site. These changes in autophosphorylation suggest that the MEN2B mutation may result in the more aggressive MEN2B phenotype by altering the receptor's signaling capabilities.
Similar articles
-
Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase.Cancer Res. 1997 Dec 1;57(23):5399-405. Cancer Res. 1997. PMID: 9393766
-
Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.Endocrinology. 1998 Aug;139(8):3613-9. doi: 10.1210/endo.139.8.6124. Endocrinology. 1998. PMID: 9681515
-
Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.Cancer Res. 2001 Feb 15;61(4):1426-31. Cancer Res. 2001. PMID: 11245446
-
Putting the bits and pieces of the RET proto-oncogene puzzle together.Bone. 1995 Aug;17(2 Suppl):13S-16S. doi: 10.1016/8756-3282(95)00200-w. Bone. 1995. PMID: 8579892 Review.
-
Oncogenic activation of the ret protooncogene in thyroid cancer.Crit Rev Oncog. 1995;6(1):35-46. doi: 10.1615/critrevoncog.v6.i1.30. Crit Rev Oncog. 1995. PMID: 8573606 Review.
Cited by
-
Personalized Medicine in Medullary Thyroid Carcinoma: A Broad Review of Emerging Treatments.J Pers Med. 2023 Jul 13;13(7):1132. doi: 10.3390/jpm13071132. J Pers Med. 2023. PMID: 37511745 Free PMC article. Review.
-
FOXA2 and STAT5A regulate oncogenic activity of KIF5B-RET fusion.Am J Cancer Res. 2023 Feb 15;13(2):638-653. eCollection 2023. Am J Cancer Res. 2023. PMID: 36895965 Free PMC article.
-
RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives.Pharmacol Ther. 2023 Feb;242:108344. doi: 10.1016/j.pharmthera.2023.108344. Epub 2023 Jan 9. Pharmacol Ther. 2023. PMID: 36632846 Free PMC article. Review.
-
RET Proto-Oncogene-Not Such an Obvious Starting Point in Cancer Therapy.Cancers (Basel). 2022 Oct 27;14(21):5298. doi: 10.3390/cancers14215298. Cancers (Basel). 2022. PMID: 36358717 Free PMC article. Review.
-
RET signaling pathway and RET inhibitors in human cancer.Front Oncol. 2022 Jul 25;12:932353. doi: 10.3389/fonc.2022.932353. eCollection 2022. Front Oncol. 2022. PMID: 35957881 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous
